Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cellectar Biosciences, Inc.CLRB · Entity 7572 | Director | July 07, 2026 | July 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cellectar Biosciences, Inc.
Report date July 07, 2026 · Filed July 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.70 · Expires 2036-07-07 | Direct | 25,000 |
Reported balance
After 2026-07-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-07 · Grant · Acquired 25,000 · Balance 25,000 F1: This option shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 07, 2026 Filed Jul 9, 2026 01:02 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001104659-26-082010 · tm2620095-2_4seq1.xml · derivative · entry 1 NEIS JOHN · CIK 0001167426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common stock · 25,000 shares Expires 2036-07-07 F1 · derivative.exercise_date: This option shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 23:00 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | SaleCommon Stock | 198 | $3.70 | $731.99 |
DisclosureSEC source: 0001104659-25-121691 · tm2533642-1_4seq1.xml · nonDerivative · entry 1 NEIS JOHN · CIK 0001167426 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 10 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.631 to $3.70, inclusive. The reporting person has provided to the Issuer, and undertakes to provide to any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnote (1) to this Form 4. F2 · balance_after: This number has been adjusted for (i) the one-for-thirty (1:30) reverse stock split effected by the Issuer on June 24, 2025, (ii) the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022, and (iii) the one-for-ten (1:10) reverse stock split effected by the Issuer on July 16, 2018. F3 · ownership.nature: These securities are held by Advantage Capital Wisconsin Partners I, Limited Partnership. Venture Investors LLC is the submanager and special limited partner of Advantage Capital Wisconsin Partners I, Limited Partnership. The investment decisions of Venture Investors LLC are made collectively by five managers, including the reporting person. The reporting person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest herein. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:06 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $0.29 | $0.00 |
DisclosureSEC source: 0001104659-25-014753 · tm256830d7_4seq1.xml · derivative · entry 1 NEIS JOHN · CIK 0001167426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2035-02-14 F1 · derivative.exercise_date: This option shall vest in full on February 14, 2026, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 21:00 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001104659-24-072881 · tm2417520-3_4seq1.xml · derivative · entry 1 NEIS JOHN · CIK 0001167426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2033-12-22 F1 · date: This option was contingently granted on December 22, 2023, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2024 Annual Meeting of Stockholders. Such stockholder approval was obtained on June 14, 2024. F2 · derivative.exercise_date: This option shall vest in full on December 22, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 28, 2023 Filed Jun 28, 2023 22:26 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001104659-23-075940 · tm2320030-4_4seq1.xml · derivative · entry 1 NEIS JOHN · CIK 0001167426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,887 Underlying: Common Stock · 25,000 shares Expires 2033-06-28 F1 · derivative.exercise_date: This stock option shall vest in full on June 28, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 24, 2022 Filed Aug 1, 2022 22:01 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 7,800 | $0.00 Strike: $4.10 | $0.00 |
DisclosureSEC source: 0001104659-22-084838 · tm2222253-4_4seq1.xml · derivative · entry 1 NEIS JOHN · CIK 0001167426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2032-06-24 F1 · derivative.exercise_price: Exercise price and quantity have been adjusted for the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022. F1 · shares: Exercise price and quantity have been adjusted for the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022. F2 · derivative.exercise_date: This stock option shall vest in full on June 24, 2023, subject to the reporting person's continued service through the applicable vesting date. F1 · derivative.underlying_shares: Exercise price and quantity have been adjusted for the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022. F1 · balance_after: Exercise price and quantity have been adjusted for the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:03 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 78,000 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001104659-21-088841 · tm2120855-5_4seq1.xml · derivative · entry 1 NEIS JOHN · CIK 0001167426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,000 Underlying: Common Stock · 78,000 shares Expires 2031-06-30 F1 · derivative.exercise_date: This option shall vest on the first anniversary of the date of grant. Read SEC document |
| March 18, 2021 Filed Mar 19, 2021 20:06 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | SaleSeries A Warrants · Derivative | 23,232 | $0.25 Strike: $30.40 | $5,859.11 |
DisclosureSEC source: 0001104659-21-039056 · tm2110277d1_4seq1.xml · derivative · entry 2 NEIS JOHN · CIK 0001167426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,323 shares Expires 2021-04-20 F2 · derivative.underlying_shares: The price reported is a weighted average price. These warrants were sold in multiple transactions at prices ranging from $0.24 and $0.27, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| March 17, 2021 Filed Mar 19, 2021 20:06 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | SaleSeries A Warrants · Derivative | 58,640 | $0.28 Strike: $30.40 | $16,272.60 |
DisclosureSEC source: 0001104659-21-039056 · tm2110277d1_4seq1.xml · derivative · entry 1 NEIS JOHN · CIK 0001167426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,232 Underlying: Common Stock · 5,864 shares Expires 2021-04-20 F1 · derivative.underlying_shares: The price reported is a weighted average price. These warrants were sold in multiple transactions at prices ranging from $0.27 and $0.2845, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 00:54 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | SaleSeries A Warrants · Derivative | 100,515 | $0.31 Strike: $30.40 | $31,069.19 |
DisclosureSEC source: 0001104659-21-037323 · tm2110008d1_4.xml · derivative · entry 3 NEIS JOHN · CIK 0001167426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,872 Underlying: Common Stock · 10,051 shares Expires 2021-04-20 F3 · derivative.underlying_shares: The price reported is a weighted average price. These warrants were sold in multiple transactions at prices ranging from $0.28 and $0.34, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 00:54 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | SaleSeries A Warrants · Derivative | 11,200 | $0.27 Strike: $30.40 | $2,970.24 |
DisclosureSEC source: 0001104659-21-037323 · tm2110008d1_4.xml · derivative · entry 2 NEIS JOHN · CIK 0001167426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,387 Underlying: Common Stock · 1,120 shares Expires 2021-04-20 F2 · derivative.underlying_shares: The price reported is a weighted average price. These warrants were sold in multiple transactions at prices ranging from $0.265 and $0.2666, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| March 12, 2021 Filed Mar 17, 2021 00:54 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | SaleSeries A Warrants · Derivative | 41,155 | $0.27 Strike: $30.40 | $10,980.15 |
DisclosureSEC source: 0001104659-21-037323 · tm2110008d1_4.xml · derivative · entry 1 NEIS JOHN · CIK 0001167426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,587 Underlying: Common Stock · 4,115 shares Expires 2021-04-20 F1 · derivative.underlying_shares: The price reported is a weighted average price. These warrants were sold in multiple transactions at prices ranging from $0.2648 and $0.27, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 20:23 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001104659-20-076873 · tm2023456d5_4.xml · derivative · entry 1 NEIS JOHN · CIK 0001167426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-06-24 F1 · derivative.exercise_date: This option grant shall vest over a period of three years from the grant date, with one-third vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 20:31 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 6,500 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001144204-19-031010 · tv523611_4.xml · derivative · entry 1 NEIS JOHN · CIK 0001167426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2029-06-13 F1 · derivative.exercise_date: Options vest on the one year anniversary of the date of grant. Read SEC document |
| October 12, 2018 Filed Oct 15, 2018 23:51 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 13,000 | $0.00 Strike: $2.61 | $0.00 |
DisclosureSEC source: 0001144204-18-053882 · tv504847_form4.xml · derivative · entry 1 NEIS JOHN · CIK 0001167426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2028-10-12 F1 · derivative.exercise_date: This option grant was divided into a definitive grant of 6,150 shares, which vest in equal monthly installments over a seven month period from the grant date, and a contingent grant of 6,850 shares, which are subject to the following conditions: (i) approval by Cellectar's stockholders of an increase in shares available under the Amended and Restated 2015 Stock Incentive Plan at the Corporation's 2019 annual meeting of stockholders or other special meeting of stockholders called for such purpose; and (ii) to the extent stockholder approval is received, the contingent grant shall vest immediately upon such stockholder approval. Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 21:04 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | SaleCommon Stock, par value $0.00001 per share | 5,214 | $1.49 | $7,790.76 |
DisclosureSEC source: 0001144204-17-059707 · tv479684_4.xml · nonDerivative · entry 1 NEIS JOHN · CIK 0001167426 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 626,103 F1 · kind: Advantage Capital Wisconsin Partners I, Limited Partnership sold 5,214 shares which represented all of its Cellectar holdings in order for the fund to make its final distributions and dissolve before the end of 2017. F2 · price: The price reported in Column 4 of Line 1 with respect to the 5,214 shares sold on November 14, 2017 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.46 to $1.53. The reporting person has provided to the Issuer, and undertakes to provide to any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in Footnote (2) to this Form 4. F3 · ownership.nature: These securities are held by Advantage Capital Wisconsin Partners I, Limited Partnership. Venture Investors LLC is the submanager and special limited partner of Advantage Capital Wisconsin Partners I, Limited Partnership. The investment decisions of Venture Investors LLC are made collectively by five managers, including the reporting person. The reporting person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest herein. Read SEC document |
| May 31, 2017 Filed Jun 1, 2017 22:02 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001144204-17-030681 · v468270_4.xml · derivative · entry 1 NEIS JOHN · CIK 0001167426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-31 F1 · derivative.exercise_date: Options vest in equal annual increments over a period of three years from the date of grant. Read SEC document |
| November 29, 2016 Filed Nov 30, 2016 23:59 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | PurchaseSeries C Warrants (right to buy) · Derivative | 333,333 | $0.01 Strike: $1.50 | $3,333.33 |
DisclosureSEC source: 0001144204-16-137317 · v454220_4.xml · derivative · entry 2 NEIS JOHN · CIK 0001167426 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 607,946 Underlying: Common Stock · 333,333 shares Expires 2021-11-29 F1 · ownership.nature: These securities are held by Venture Investors Early Stage fund IV Limited Partnership and Advantage Capital Wisconsin Partners I, Limited Partnership. VIESF IV GP LLC is the general partner of Venture Investors Early Stage Fund IV Limited Partnership and Venture Investors LLC is the submanager and special limited partner of Advantage Capital Wisconsin Partners I, Limited Partnership. The investment decisions of VIESF IV GP LLC and Venture Investors LLC are made collectively by seven managers, including the reporting person. The reporting person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest herein. Read SEC document |
| November 29, 2016 Filed Nov 30, 2016 23:59 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | PurchaseCommon Stock, par value $0.00001 per share | 333,333 | $1.49 | $496,666.17 |
DisclosureSEC source: 0001144204-16-137317 · v454220_4.xml · nonDerivative · entry 1 NEIS JOHN · CIK 0001167426 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 631,317 F1 · ownership.nature: These securities are held by Venture Investors Early Stage fund IV Limited Partnership and Advantage Capital Wisconsin Partners I, Limited Partnership. VIESF IV GP LLC is the general partner of Venture Investors Early Stage Fund IV Limited Partnership and Venture Investors LLC is the submanager and special limited partner of Advantage Capital Wisconsin Partners I, Limited Partnership. The investment decisions of VIESF IV GP LLC and Venture Investors LLC are made collectively by seven managers, including the reporting person. The reporting person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest herein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.